West Pharmaceutical Services (WST Quick QuoteWST - Free Report) stock has surged 38.1% since the beginning of the second quarter, significantly outperforming its industry’s 9% gain and the S&P 500’s 18.6% growth.

The rally is supported by a sharp improvement in operating momentum, with WST delivering a 13% organic revenue increase and 29% adjusted earnings per share (EPS) growth in the second quarter. Management raised its 2026 outlook, now expecting 10-11% organic revenue growth.

The company’s high-value proprietary products, particularly components used in biologics and GLP-1 therapies, are generating strong demand. Improving manufacturing productivity, favorable product mix and recovery from the cyber incident further strengthen the earnings outlook, providing fundamental support for the stock’s outperformance.

Image Source: Zacks Investment Research

Factors Benefiting WST

Biologics and Biosimilars Strengthen HVP Momentum: Biologics are becoming an increasingly important growth engine for WST. Proprietary Products grew 16% organically in the second quarter, while its Biologics business jumped 29%. HVP Components increased 18.4% and represented 49% of revenues, up from 46% a year earlier. WST also maintains a win rate of more than 90% on new large-molecule drugs, positioning it to benefit from the growing adoption of biologics and biosimilars.

Annex 1 Upgrades Are Creating a Multiyear Mix Tailwind: West Pharma is benefiting from customers upgrading toward higher-value primary containment solutions to comply with evolving manufacturing standards, including Annex 1. These upgrades often involve additional finishing processes such as Envision inspection, supporting both revenues and margins. Management believes the opportunity remains in its early stages and expects the shift toward HVP upgrades to contribute approximately 200 basis points to revenue growth in 2026.

GLP-1 Demand Is Expanding Beyond the Initial Opportunity: GLP-1-related HVP Components delivered high-teens organic growth in the second quarter, slightly ahead of expectations. WST expects double-digit growth to continue through the rest of 2026 as injectable and generic GLP-1 launches expand globally. The company is well positioned to benefit from next-generation therapies for obesity, diabetes, and other metabolic conditions, which may require more sophisticated primary-containment solutions.

Delivery Devices and Productivity Are Adding Incremental Upside: HVP Delivery Devices surged 29% organically in the second quarter, led by strong performance across SelfDose and Crystal Zenith, while Asia Pacific delivered 27% organic growth. Manufacturing productivity is also improving, particularly at Eschweiler, where throughput increased a double-digit percentage. These gains helped WST recover from the cyber incident and provide additional capacity to support demand without relying solely on new facilities.

West Pharmaceutical Services, Inc. Revenue (Quarterly YoY Growth)

West Pharmaceutical Services, Inc. revenue-quarterly-yoy-growth | West Pharmaceutical Services, Inc. Quote

Competition

West Pharma is currently demonstrating stronger growth than its major packaging and healthcare-component peers. Baxter (BAX Quick QuoteBAX - Free Report) delivered 5% organic growth in the second quarter, led by Advanced Surgery and Drug Compounding, but its Novum IQ LVP remediation remains an operational overhang. Becton, Dickinson and Company (BDX Quick QuoteBDX - Free Report) reported 4.4% revenue growth, although its BioPharma Systems business benefited from double-digit biologics growth and mid-teens growth excluding vaccines. AptarGroup (ATR Quick QuoteATR - Free Report) posted 6% reported sales growth, while Pharma core sales increased only 1%. Excluding emergency medicine, Pharma grew 8%, with injectables up 9%.

The comparison favors West Pharma because Baxter is still navigating product and supply issues, while Becton, Dickinson and Companyand AptarGrouphave broader portfolios that dilute exposure to high-growth pharmaceutical components. Baxter’s 5% rise, Becton, Dickinson and Company’s4.4% improvement and AptarGroup’s 6% reported growth trail West Pharma’s 13% organic expansion. BDX and ATR, however, remain meaningful competitors in biologics, injectable delivery and elastomeric components, making innovation and customer retention critical for WST.

Risks and Challenges

WST’s biggest near-term risk is execution as it completes its recovery from the cyber incident and works through delayed West Vantage revenues. Management expects some lost second-quarter revenues to shift into the second half, although the timing remains uncertain. Pricing contributed 4 percentage points to second-quarter growth, above the company’s normal 2-3% range, creating a tougher comparison ahead. Capacity utilization at key HVP facilities, along with geopolitical and input-cost pressures, could also constrain margins.

Conclusion

Strong upmove in WST’s share price since the end of March reflects a fundamental acceleration rather than merely market momentum. Strong HVP demand, GLP-1 exposure, Annex 1 upgrades and improving productivity support further growth. With WST carrying a Zacks Rank #2 (Buy), the stock retains a favorable growth profile, although execution and valuation will remain important considerations for investors. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.